Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? by Olivier, Timothée et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Cancer Biology Faculty Papers Department of Cancer Biology 
4-5-2021 
Redefining cancer of unknown primary: Is precision medicine 






See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/cbfp 
 Part of the Cancer Biology Commons, and the Oncology Commons 
Let us know how access to this document benefits you 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Cancer Biology Faculty Papers by an authorized administrator of the 
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Authors 
Timothée Olivier, Eugenio Fernandez, Intidhar Labidi-Galy, Pierre-Yves Dietrich, Veronica Rodriguez-Bravo, 
Giulia Baciarello, Karim Fizazi, and Anna Patrikidou 
Cancer Treatment Reviews 97 (2021) 102204
Available online 5 April 2021
0305-7372/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Tumour Review 
Redefining cancer of unknown primary: Is precision medicine really 
shifting the paradigm? 
Timothée Olivier a,*, Eugenio Fernandez a, Intidhar Labidi-Galy a,b,c, Pierre-Yves Dietrich a,b,c, 
Veronica Rodriguez-Bravo d, Giulia Baciarello e, Karim Fizazi f,1, Anna Patrikidou g,h,1 
a Department of Oncology, Geneva University Hospital, Switzerland 
b Translational Research Centre in Oncohaematology (CRTOH), University of Geneva, Switzerland 
c Swiss Cancer Center Leman, Switzerland 
d Cancer Biology Department, Thomas Jefferson University, Philadelphia, USA 
e Department of Cancer Medicine, Gustave Roussy, Villejuif, France 
f Department of Cancer Medicine, Gustave Roussy, University of Paris Saclay, Villejuif, France 
g Drug Development Unit, Sarah Cannon Research Institute, London, UK 
h UCL Cancer Institute, University College London, UK   
A R T I C L E  I N F O   
Keywords: 
Chromosomal instability (CIN) 
Classifier assay 
Clinical trial 
Cancer of unknown primary (CUP) 
Metastasis 
A B S T R A C T   
The concept of Cancer of Unknown Primary (CUP) has evolved with the advent of medical oncology. CUP can be 
difficult to diagnose and represents 2 to 5% of new cancers, therefore not exceptionally rare. Within CUPs can be 
identified a subset of favourable prognosis tumours, however the vast majority of CUP patients belongs to a poor 
prognosis group. 
CUP features significant oncological challenges, such as unravelling biological and transversal issues, and most 
importantly, improving patient’s outcomes. In that regard, CUP patients’ outcomes regrettably showed minimal 
improvement for decades and CUP remains a cancer group of very poor prognosis. 
The biology of CUP has two main hypotheses. One is that CUP is a subgroup of a given primary cancer, where 
the primary is present but cannot be seen due to its small size. The other, the “true” CUP hypothesis, states that 
CUP share features that make them a specific entity, whatever their tissue of origin. A true biological signature 
has not yet been described, but chromosomal instability is a hallmark of poor prognosis CUP group. 
Precision oncology, despite achieving identifying the putative origin of the CUP, so far failed to globally 
improve outcomes of patients. Targeting molecular pathways based on molecular analysis in CUP management is 
under investigation. Immunotherapy has not shown ground-breaking results, to date. Accrual is also a crucial 
issue in CUP trials. 
Herein we review CUP history, biological features and remaining questions in CUP biology, the two main 
approaches of molecular oncology in CUP management, in order to draw perspectives in the enormous challenge 
of improving CUP patient outcomes.   
Introduction 
An enigmatic entity, cancer of unknown primary (CUP), has evolved 
alongside the development of modern oncology. The first mention of 
cancer with “unknown primary” dates back to 1946 [1]. Since that time, 
a shift in the definition and diagnosis occurred, associated with the 
emergence of ever more sophisticated diagnostic tools which aim to 
trace biological and molecular similarities to the elusive, possibly 
dormant or regressed, primary [2]. 
Epidemiology - prognosis 
Epidemiology 
CUP is defined by the absence of a clinically identified primary lesion 
(the primary is not “seen”) at the time of diagnosis despite standardised 
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diagnostic work-up [3–5]. 
Confirmed CUPs represent 2 to 5% of all cancers [5] and 15% of all 
new cancers are presenting as malignancy of unknown origin (MUO) 
[4]. 
CUPs incidence is varying across countries [5]. Differences may be 
explained by coding rules and methodology in cancer registries [6]. Cost 
issues can explain underreporting of CUP: in the US, costs are better 
covered for specific cancers in comparison with CUPs [7]. In contrast, 
CUP incidence has been related to be higher in patient with lower in-
come, possibly due to insufficient diagnostic inquiry [7,8]. 
Incidence has increased since CUP concept was introduced, to reach 
a peak at the end of 1990′s in most countries [5]. After the tipping point, 
the decreasing number of diagnosed CUPs is mainly explained by better 
identification of small primary lesion. Decreased incidence of some 
primary cancers (lung) could also account in the decrease in CUPs 
incidence. 
Favourable And Unfavourable Subgroups Of CUPs 
CUP can be divided in two subgroups with very different prognosis, 
treatment, and expected outcomes: the favourable (15–20%) and the 
unfavourable (80 – 85%) subgroups [3,9]. 
For patients presenting with CUPs belonging to the favourable sub-
group, principles of treatment are mostly derived from the treatment of 
their corresponding known primaries. Nine specific situations are 
identified to belong to the favourable subgroups, with a corresponding 
tailored treatment recommendation based on the equivalent known 
primary tumour. This is well described in international guidelines 
[3,9,10], this situations are: 
- poorly differentiated neuroendocrine carcinomas of unknown 
primary 
- well-differentiated neuroendocrine tumour of unknown primary 
- peritoneal adenocarcinomatosis of a serous papillary in females 
- isolated axillary nodal metastases in females 
- squamous cell carcinoma (SCC) involving non-supraclavicular 
cervical lymph nodes (head-and-neck) 
- CUP with a colorectal profile (immunohistochemistry (IHC) or 
molecular) 
- single metastatic deposit from unknown primary 
- men with blastic bone metastases or IHC/serum PSA expression, 
- isolated inguinal adenopathy (SCC) 
Prognosis is better in these entities, with curative intent in some of 
them. As an example, the isolated axillary nodal metastases will be 
treated like a primary breast cancer with 3-year survival rate up to 97%, 
and women with peritoneal carcinomatosis of a serous papillary 
adenocarcinoma will have outcomes in the range of stage III and IV 
ovarian cancer patients [10]. 
Prognosis in the unfavourable subgroup of CUPs 
Table 1 describes outcomes from randomized trials in CUPs. Early 
trials reported dramatically short median survival (few weeks). In more 
recent trials within the unfavourable subgroup, median overall survival 
is around 1 year, up to 13.6 months [11]. Such discrepancy may reflect 
changes in inclusion criteria, and a strong selection bias favouring 
enrolment of patients with better prognosis in recent trials. 
Prognosis of CUP patients is generally worse than those with known 
primary cancers [12]. Among the unfavourable subgroup of newly 
diagnosed CUP patients, the most widely used prognostic model is based 
on the LDH level and the performance status (PS), separating a good 
prognosis group (PS = 0–1, normal LDH or absence of liver metastasis if 
LDH unknown) with a predicted 11.7 months median survival, and a 
Table 1 
Randomized clinical trials studying specifically CUP.  
Author (year) (number of 
patients) 





Woods et al. (1980) 75 





1.6 4.5% NS 
Doxorubicin, mitomycin-C 4.1 36% 
Shildt et al. (1983) 76 
(n = 36) 




Milliken et al. (1987) 78 
(n = 101) 
Adenocarcinoma, 
undifferentiated 
Doxorubicin, mitomycin-C 4.1 42% NS 
Cisplatin, bleomycin, vinblastin 5.7 32% 
Eagan et al. (1987) 77 
(n = 55) 
Carcinoma (50/55 
adenocarcinomas) 
Doxorubicin, mitomycin-C 5.5 14% NS 
Cisplatin, doxorubicin, mitomycin-C 4.6 27% 
Falkson et al. (1998) 79 
(n = 84) 
Adenocarcinoma, 
undifferentiated 
Cisplatin, epirubicin, mitomycin-C 9.4 50% 0.05 
Mitomycin-C 5.4 17% 
Dowell et al. (2001) 80 
(n = 34) 
Adenocarcinoma, 
undifferentiated 
Paclitaxel, 5-fluorouracil, leucovorin 8.2 19% NS 
Carboplatin, etoposide 6.4 19% 
Assersohn et al. (2003) 81 
(n = 88) 
Carcinoma 5-Fluorouracil 6.6 11.6% NS 
5-Fluorouracil, mitomycin-C 4.7 20% 
Culine et al. (2003) 83 
(n = 80) 
Carcinoma Cisplatin, gemcitabine 8 55% NS 
Cisplatin, irinotecan 6 38% 
Palmeri et al. (2006) 11 
(n = 66) 
Carcinoma Cisplatin, gemcitabine, vinorelbine 13.6 48.5% NS 
Cisplatin, paclitaxel, gemcitabine 9.6 42.3% 
Huebner et al. (2009) 84 
(n = 92) 
Adenocarcinoma, 
undifferentiated 
Carboplatin, paclitaxel 11 23.8% NS 
Gemcitabine, vinorelbine 6.9 20% 
Hainsworth et al. (2010) 85 
(n = 198) 
Carcinoma Paclitaxel, carboplatin, etoposide then 
gefitinib 
7.4 18% NS 
Gemcitabine, irinotecan then gefitinib 8.5 18% 
Gross-Goupil et al. (2012) 86 
(n = 52) 
Carcinoma Cisplatin 8 16% NS 
Cisplatin, gemcitabine 11 19% 
Hainsworth et al. (2015) 74 
(n = 89) 
Carcinoma Carboplatin, paclitaxel, belinostat 12.4 45% NS OS 
P less than 0.02 
ORR 
Carboplatin, paclitaxel 9.1 21% 
Hayashi et al. (2019) 88 
(n = 130) 
Carcinoma Carboplatin, paclitaxel 12.5 41.2% NS 
Site-specific therapy 9.8 34.7% 
Fizazi et al. (2019) 89 
(n = 243) 
Carcinoma Cisplatin, gemcitabine 10 NA NS 
Site-specific therapy 10.7 
p = p-value for statistical significance for overall survival; NS = not statistically significant, OS = overall survival, ORR = overall response rate, NA = not available 
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poor prognosis group (PS > 1 or elevated LDH) with 3.9 months median 
survival [13]. This model was based on retrospective data, with a third 
of patients included being part of prospective trials, with probably 
overestimation of survival in comparison with real world outcomes. 
Indeed, data from the Surveillance, Epidemiology, and End Results 
(SEER) registry analysis up to 2008 shows dismal survival after CUP 
diagnosis with a median survival of 3 months, making CUP the fourth 
more lethal cancer in the world [8]. 
Over time, there were almost no improvement in prognosis [14], 
with survival improving only in the subset of patients with squamous 
cell carcinoma [8]. Within this study, there is no distinction between the 
favourable and unfavourable subgroup of CUPs: it is likely that most of 
the patients were belonging to the unfavourable subgroup of CUPs. The 
longitudinal analysis of the SEER registry (1973 to 2008) showed a 
better survival (after multivariate analysis) for white race, female, age 
under 65, married people, squamous histology, diagnosis done in the 
most recent decade, and treatment with radiotherapy [8]. 
Diagnosis And The Tissue Of Origin Concept 
Diagnosis is established after pathological examination of a good 
quality tissue sample (biopsy or, more rarely, cytology). Diagnostic 
workup aims to exclude non-carcinomatous tumours (lymphomas, 
melanomas, germ cell tumours, sarcomas), which account for less than 
5% of findings, but point towards the elusive primary and require very 
specific treatments. Consequently, CUPs are almost exclusively carci-
nomas, explaining why the term CUP is also used for “carcinoma” of 
unknown primary origin. 
The availability of advanced imaging and endoscopy technologies, 
serum marker testing, the development of immunohistochemical panel 
testing and the increasing access to gene profiling and other molecular 
analyses, including epigenetics [15,16] allow suspecting a tissue of 
origin in a growing subset of CUPs, even in the absence of anatomically 
identified primary [17,18]. The European Society of Medical Oncology 
(ESMO) guidelines suggest a basic immunohistochemical (IHC) work-up 
for CUPs, divided in a minimum set of primary markers, to initially 
direct towards subsets of potential primaries, followed by a set of 
additional markers towards the final identification of the putative pri-
mary tumour, endorsing a previously described two-step procedure 
[3,19]. Two CUP groups can be distinguished: tissue of origin-defined 
CUP and unclassifiable CUP [17], the latter corresponding to the 
confirmed CUP for which neither an identifiable primary site nor a 
suggested tissue of origin exists. 
With the use of more advanced assays (such as microarrays and next 
generation sequencing), a putative tissue of origin can be identified in 
approximately 80%-85% of cases [15,16]. 
An integrative illustration of these definitions and of the way the 
diagnostic work-up of CUP is currently shaped is presented in Fig. 1. 
Tissue Of Origin Classifier Assays 
Driven by the hypothesis that the identification of a primary tumour 
could lead to more specific treatment and therefore would improve 
patient’s outcomes, several molecular assays were developed in order to 
identify the tissue of origin in CUPs with more accuracy. 
Based on gene expression profiling, miRNA expression or DNA 
methylation analysis, these tests compare the molecular features of the 
CUP to the molecular profile of tumours of known origin, therefore 
inferring a putative tissue of origin. Because no gold standard test 
defining the tissue of origin exists in CUP, the assessment and validation 
of the performance of these classifiers are challenging [2,20]. 
Several retrospective studies have attempted to assess the prediction 
accuracy of these tests performed on biopsy specimens from patients 
with CUP. Using correlation with clinicopathological features, the IHC 
profile or the identification of a latent primary as prediction comparator, 
these molecular based tissue of origin classifiers yield prediction accu-
racy from 60% to 92% [15,21–30]. This is corroborated by a prospective 
study demonstrating an 84% agreement of molecular profile with clin-
icopathological diagnosis [31]. 
One approach, illustrated by the work of Moran et al., is based on the 
epigenetic profiling via analysis of DNA methylation, developing an 
assay called EPICUP® DNA methylation profiling. This was developed 
from the analysis of 2790 tumour samples and validated in 7691 known 
tumour samples, with 87% prediction of a primary [27]. 
MicroRNA profiling is another technique, that has been studied in a 
prospective study [31]. The analysis of formalin-fixed paraffin- 
embedded (FFPE) metastatic tissues from 104 patients using a subset of 
48 microRNAs led to a 71% accuracy in predicting the tissue of origin. 
Ferracin et al. used a similar approach with a 47-miRNA signature, 
reaching a 100% accuracy for primary tumours and 78% for metastasis 
from known primary tumours, with an accuracy for CUP tested in only 
16 patients [24]. 
Another approach is based on the analysis of gene expression 
profiling. Horlings et al. obtain whole gene expression data using 
microarray technology from FFPE classifying correctly 81% of metas-
tasis to their known primaries. A primary origin was assigned in almost 
94% of ACUP (adenocarcinoma of unknown primary origin) [22]. Even 
if the microarray technology is not the most used today, this study 
Fig. 1.  
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confirmed that gene expression analysis can yield high predictive ac-
curacy in determining tissue of origin in CUPs. 
Some limitations in the analysis of gene expression in CUP could be 
overcome by performing more sophisticated analysis, allowing more 
comparison with available datasets for all tumour cases. These types of 
approaches were implemented in a recent study, with machine learning 
analysing 77,044 DNA sequencing and whole transcriptome data. Even 
with such sophisticated tools, this yields in 71.7% of prediction in CUPs. 
This approach also have the originality to provide, at the same time, 
results about potential targetable genomic alteration [30]. 
Biological landscape 
Biological hypothesis 
Tumorigenesis of CUPs, and how to explain the absence of a 
detectable primary, remain matters of debate, with two main hypotheses 
[32,33]. The first hypothesis considers each CUP as a subtype of its 
corresponding known primary cancer with a primary lesion too small or 
too difficult to detect. This disease would, therefore, share clinical fea-
tures with the corresponding primary and could benefit from the same 
treatment. An example is high-grade serous peritoneal carcinoma that 
could arise from early lesions in the Fallopian tube. These early lesions 
are undetectable if extensive sampling of the Fallopian tubes is not 
undertaken. 
The second hypothesis suggests that the absence of the primary 
lesion is real, and will persist during the course of the disease, most 
probably due to its early and maintained regression or dormancy. CUPs, 
in relation to these early biological events, would be a specific entity, 
and share similarities whatever their tissue of origin, making them a 
complete distinct entity from known primary tumours: this is the “true” 
or “genuine” CUP hypothesis [32,33]. The parallel progression model of 
tumorigenesis could support this hypothesis, as independent clonal 
evolution under differential selection pressure could explain the 
regression of a primary lesion (that could be immune-mediated [34]) 
along with growing metastatic lesions [35,36]. 
Favouring the first hypothesis, a number of CUP patients (ranging 
from 4% to 25% in the reported literature) will subsequently, during the 
course of the disease, present a primary lesion [2]. Furthermore, autopsy 
studies led to identification of a primary lesion in 73% of CUPs cases, 
with variation across studies [20]. Nevertheless, a substantial group of 
CUP patients remains without an identified primary lesion. 
The ability of molecular classifiers to infer a tissue of origin in the 
vast majority of cases argues in favour of biological proximity between 
CUPs and known primary cancers [37]. Moreover, a study that 
compared microRNA profiles of CUPs metastases with those from pri-
mary tissue-matched metastases of known primaries did not detect 
substantial differences. An important limitation of this work was that all 
CUPs cases were belonging to the favourable subgroups of CUPs [38]. 
Nevertheless, discrepancies between putative primary lesions found 
in autopsy studies and through molecular analyses cast doubt on their 
perfect reliability, even though those studies were not conducted at the 
same periods of time [33]. Several works failed to identify a unique 
“molecular CUP signature” [2,32], consequently weakening the “true” 
CUP hypothesis. 
Chromosomal instability as a hallmark of CUPs? 
The “true” CUP hypothesis states that CUPs, whatever their cell-of- 
origin, share similarities and could be addressed as a specific entity. 
Unfavourable CUPs are definitively sharing clinical characteristics that 
distinguish them from other cancers: aggressive phenotype with rapid 
growing metastases, unpredictable metastatic pattern, poor response to 
chemotherapy and poor clinical outcomes [20]. CUP metastases occur 
early and subsequently undergo genetic evolution toward a highly 
complex and unbalanced cytogenetic aberrations independent from the 
primary tumour [33,39]. Many of these genome aberrations originate 
from a persistent rate of chromosome missegregation during cell divi-
sion, a phenomenon known as Chromosomal Instability (CIN) [40,41], 
which in turn can lead to whole chromosome losses and gains (aneu-
ploidy) [42] or to other dramatic genome aberrations. It is recognised 
that CIN drives cancer aggressiveness by increasing tumour heteroge-
neity and genetic diversity within the tumour cell population, which 
allows adaptation to unfavourable conditions and therapy resistance 
[43] not only to conventional chemotherapy, but to immunotherapy as 
well [44]. Furthermore, CIN has been suggested to directly drive the 
metastatic process itself [45], and is associated with poor clinical out-
comes [39,46,47]. 
Tumour metastasis is a clonal process driven by CIN, through which 
metastatic cancer cells acquire chromosome segments that encode genes 
endering survival benefit and metastasising potential [45,48]. A work 
conducted by Vikesa and colleagues showed that CUPs, in comparison 
with metastases of known origin, presented microRNA signatures of CIN 
[49]. While reviewing details from the 57 cases that are described, we 
estimate that only 4 of them could have belong to the favourable sub-
group of CUP (3 colon cancer and 1 cervical cancer presenting with 
inguinal lymph node), suggesting that CIN is exclusive to the poor 
prognosis subgroup of CUP but this should be confirm in other studies. It 
can therefore be postulated that CIN facilitates independent progression 
of metastatic sites in CUP following early dissemination and primary 
tumour regression/dormancy (possibly as the latter are less chromoso-
mally instable). One could hypothesise that this could be a consequence 
of early CIN increase accumulating already in locally advanced primary 
tumours, which then could either grow enough in size to be detectable or 
stay genomically unstable but small in size, challenging identification, 
or even experience regression while some cells have been able to 
disseminate to distant organs. This scenario would fit well with the most 
predominantly mutated gene found in CUPs, the TP53 gene. Such mu-
tations, if acquired early during tumorigenesis could allow permissive 
conditions for accumulation of CIN and derived alterations, allowing 
cancer cells to continue diving and propagating instead of being elimi-
nated [50,51]. The prevalence of TP53 mutations in CUPs is found to be 
in the same range as the average TP53 mutation rate across all tumour 
types (TP53 is mutated in approximately 50% of all human cancers [52]. 
In favour of fast genetic evolution increasing aggressiveness in CUPs, 
the role of other CIN-related events such as chromothripsis could be 
considered. It has been recently postulated that even one single wrong 
chromosomal segregation in one cell division can lead to a mutational 
cascade fuelling evolution and subclonal heterogeneity in cancers [53], 
suggesting that clonal evolution of tumours could in fact start very early. 
Although CIN accelerates phenotypic adaptation under selective 
pressures, very high CIN levels are counter-productive for tumour sur-
vival owing to frequent generation of unviable phenotypes. In this 
context, it is CIN tolerance and attenuation mechanisms that allow an 
optimal equilibrium and sustainable CIN propagation[43]. 
It would, therefore, be of interest to investigate CIN levels in CUPs as 
a potential explanation for their specific nature and behaviour. 
Some studies indicate that cytotoxic therapies induce CIN, and 
combination therapy with taxanes may synergize together [54,55]. 
In our view, early dissemination in the parallel progression, along 
with early chromosomal instability in metastatic clones or at the level of 
locally advanced disease, has biological robustness and could be hall-
marks of CUP tumorigenesis. We provide an illustration of this notion in 
Fig. 2. The existence of other pro-metastatic hallmarks/signatures that 
could transcend tissue of origin signature in CUPs is not excluded and 
could lie in other “-omics” levels (DNA methylation, histone acetylation, 
proteomics, non-coding regions) [38,56]. Even in the absence of final 
answers on the biology of CUP, recognising the possibility of the “true 
CUP hypothesis” could be important for clinicians in the direction of 
avoiding endless diagnostic work-up (in order to find the primary) in 
patients requiring rapid treatment initiation. Furthermore, considering 
the relevant role of CIN in the aggressiveness of CUPs, it could serve in 
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the future as an important diagnostic marker as well as a targetable axis 
in these types of tumours. 
Genomic alteration in CUPs 
Several studies retrospectively examined the genomic landscape of 
CUPs through DNA profiling (Table 2). 
In a large retrospective cohort (1806 patients), Gatalica and col-
leagues found EGFR and ERBB2 amplification as the most common 
amplifications. TP53 (38%) and KRAS (18%) were the most common 
mutated genes [57]. A retrospective analysis of 303 CUP patients whose 
archival tumour specimens underwent next-generation sequencing 
revealed that 32% would have been potentially eligible for the available 
molecularly guided targeted or immunotherapy treatment options [58]. 
This technology is the basis for target identification and management 
strategy in the ongoing CUPISCO trial (NCT03498521, see below). 
Among 333 patients with CUPs evaluated in Memorial Sloan Kettering 
Cancer Center (MSKCC), 150 of them had a genomic analysis through 
the inclusion in MSK-IMPACT [59]. The most commonly mutated genes 
were TP53, KRAS, CDKN2A, KEAP1, and SMARCA4. Authors identified 
45 (30%) patients with potentially targetable alterations and 15 (10%) 
actually received targeted therapies. Among the latter, time to treatment 
failure ranged from less than 1 month to 14 months [60]. 
The means through which these alterations could be detected is a 
major subject of research. Liquid biopsy techniques offer many advan-
tages, notably in cases of no or minimal archival tissue availability [2]. 
At the 2020 annual meeting of the American Society of Clinical 
Oncology (ASCO) the results of cell-free DNA analysis from the largest 
cohort to date of in CUP patients were presented [61]. In their work, 
90% of patients had at least one cell-free DNA (cfDNA) alteration. When 
classifying alterations according to the OncoKB annotation [62], the 
authors found that 46% of patients with at least one alteration were 
presenting with level 1, level 2B or resistance alteration (level R1). 
Importantly, 22% of the patients with at least 1 cfDNA alteration pre-
sented at least one Level 1 alteration (FDA-recognised biomarker pre-
dictive of response to FDA-approved drug in this indication), such as 
PIK3CA oncogenic mutations (22%), ERBB2 amplification (13%), 
BRCA1 (7%) and BRCA2 (9%) oncogenic mutations, BRAF V600E mu-
tation (8%) and ALK fusion (2%), amongst others [61]. 
Interpretation regarding whether these mutations could be 
targetable shows wide discrepancy according to studies, varying from 
15% to 85% [57,60,63–69]. Such analyses highlight the need to keep a 
high level of stringency in defining a “clinically relevant” alteration, 
which should go beyond bio-plausibility, and ideally rely on improved 
clinical outcomes associated with targeting such alterations, but also 
access to relevant approved targeted agents in diverse healthcare 
settings. 
The NOMINATOR study assessed the feasibility of genomic testing in 
rare cancers [70], also assessing actionability as per the OncoKB anno-
tation [62]. This work optimistically reports 56% of rare tumours with at 
least one actionable finding. The most commonly found aberrant genes 
included TP53 (44%), CDKN2A/B (14%), RB1 (14%), PTEN (13%) and 
NF1 (12%). However, in order to obtain this high percentage of 
actionable findings, the authors included OncoKB level 1 to 4; if the 
analysis was to be restricted to biomarkers with at least compelling 
clinical evidence of utility (rather than including Level 4 alterations for 
which only compelling biological evidence exists), the respective per-
centage would be 27%. The authors also exclude from their analysis the 
patients in whom the analysis could not be done (initial attrition rate of 
18%), introducing therefore an overestimation in the estimation of 
percentage of “clinically relevant” alterations. Furthermore, only 13 out 
of 121 (11%) patients ultimately had access to a matched drug, and 
outcomes are not reported, hence the real impact strength was not 
accurately assessed. 
Results are awaited for the RP-1843 Arcagen collaborative project of 
the EORTC-SPECTA cohorts [71], aiming to perform comprehensive 
molecular analysis in a 2100-strong cohort of rare cancer patients. An 
initial report of 87 patients with sarcoma, thymic cancer, rare ovarian 
and head or neck cancers reported a 47% incidence of clinically relevant 
genomic alteration, with a 14% analysis failure rate [72]. 
Immune microenvironment and immune biomarkers in CUPs 
Few data are available on tumour immune microenvironment in 
CUPs. One study reported no prognostic value of the presence of CD8 
positive tumour–infiltrating lymphocytes (TILs) by IHC on a cohort of 92 
CUPs. Transcriptional analysis on 71 cases revealed two sub-groups: 
inflamed and non-inflamed. Interestingly, there was inverse associa-
tion between levels of VEGF-A gene and inflamed phenotype, suggesting 
that VEGF blockade may enhance anti-PD1/PD-L1 in CUPs [73]. 
Fig. 2.  
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Another study analysed 592 genes of 389 CUPs cases, showing that 28% 
of them had at least one potential predictive biomarker to CPI response, 
such as PD-L1 overexpression, MSI-H profile, or high TMB [66]. 
The incidence of patients with MSI-H profile CUPs is globally low, 
with some variation depending on analysis technique: 1.6% with next- 
generation sequencing (NGS) analysis and immunohistochemistry [66] 
and 2.4% via cfDNA analysis [61]. 
Table 3 illustrate data of potential predictive biomarkers of response 
to immune checkpoint inhibitors in CUP. 
How Effective Is The Current Standard Of Care? 
One-size fits all approach 
With the exception of the specific subsets of CUPs of favourable 
prognosis (15%-20% of CUPs) that require specific treatments, doublet 
combination chemotherapies, including platinum and taxanes, or other 
doublet chemotherapies with new compounds, are accepted standard 
“empiric” chemotherapy regimens in international guidelines [3]. They 
should be selected according to local expertise and facilities and 
considering toxicity profiles and patient comorbidities. 
Table 1 presents all existing randomized trials specifically studying 
CUP patients, with the regimens and their respective median overall 
survival and response rates when available [11,74–89]. As described, 
the prognostic classification (based on performance status and LDH 
levels) separates a favourable prognosis subgroup (median survival of 
12 months) from a poor prognosis subgroup (median survival of 4 
months); for the latter, best supportive care should also be considered 
upfront in the management algorithm [3,13]. 
A systematic review of randomised trials, excluding data from the 
specific favourable subsets of CUPs, showed no significant benefit for 
any treatment group over others (including platinum compounds, tax-
anes, gemcitabine, vinca-alkaloid and irinotecan). Hazard ratios for 
death of combination treatments containing taxanes, platinum or both 
showed a favourable trend over monotherapy with agent other than 
platinum or taxanes [90]. Another meta-analysis based on 32 studies 
showed a trend toward better survival outcome with platinum or taxane 
treatment. After adjustment for prognostic factors this trend was no 
longer significant for platinum vs non-platinum based regimen, while 
taxane-based regimens remained significant [91]. 
A phase III trial in 198 patients compared a triplet combination 
(paclitaxel/carboplatin/etoposide) with a gemcitabine/irinotecan 
combination: the triplet regimen was not superior and more toxic [85]. 
Doublet chemotherapy seems better than monotherapy regarding 
objective response rate (ORR) and is the first choice when feasible [92]. 
However, this has not been prospectively proved to be significant [86]. 
In further lines, chemotherapy is for a very selected population, with 
no trials featuring best supportive care as a comparative arm. Response 
rates are usually around 10% with median OS ranging from 3 to 9.7 
months [92]. 
Tissue of origin-based chemotherapy 
If CUPs share a “biological signature”, they would behave similarly 
whatever their tissue of origin. On the contrary, if CUPs are rather a 
subgroup of their corresponding primary, patients would benefit more 
from a tissue of origin-tailored treatment. In favour of the last hypothesis 
is the subgroup of specific subset of favourable CUPs, mainly composed 
of subtypes of entities that are closed to their known primary. 
A substantial proportion of CUPs present with relatively chemo- 
resistant tissue of origin tumours (pancreas, biliary tract) [20]. Other 
CUPs, presenting with chemosensitive tumours (ovarian, breast), will be 
likely to respond to “empiric” chemotherapy whatever their tissue of 
origin. Treatment strategies for certain primaries have considerably 
changed during the last decades, as for lung cancer, with checkpoint 
inhibitors (CPI) and tyrosine kinase Inhibitors (TKI) being incorporated 
into standard-of-care. Hence, a randomised trial comparing the efficacy 
of “empiric” chemotherapy to a “classifier-directed treatment” was 
required. 
A large prospective non-randomized phase II trial studied outcomes 
of 194 patients CUP patients receiving assay-directed site-specific 
Table 2 




Gene mutations Chromosomal abnormalities 
Amplifications Deletions 
Ross et al. (2020) 
58 
(n = 303) 





(10%); PTEN (7%); 
PIK3CA (9%); 
ERBB2 (8%); BRAF 
(6%); NF1 (4%) 
CDKN2A; CDKN2B; 






Galatica et al. 
(2018) 66 
(n = 389) 





CCND1 (5%); FGF 
(3%); ERBB2 (3%); 
MYC (3%) 
ND 
Clynick et al. 
(2018) 68 
(n = 21) 
TP53 (47%); KRAS 
(12%); MET (12%)  
MYC (12%); CCND1 
(6%); FGFR1 (6%) 
ND 
Varghese et al. 
(2017) 60 








Subbiah et al. 
(2017) 69 








Löffler et al. 
(2016) 67 
(n = 128) 
TP53 (55%); 
CDKN2A (9%); 
KRAS (16%); BRAF 
(5%); EGFR (4%) 
FGFR3 (5%); NRAS 
(5%); ERBB2 (4%); 
MET (4%); EGFR 




Ross et al. (2015) 
63 
(n = 200) 
TP53 (55%); KRAS 
(19%); ARID1A 
(11%); PIK3CA 
(7%); BRAF (6%); 
ERBB2 (4%) 
MYC (12%); MCL1 




et al. (2014) * 65 
(n = 87) 
CTNNB1 (20%); 
KRAS (12%); 
PIK3CA (9%); MET 
(7%); BRAF (6%) 
ND ND 
Galatica et al. 
(2014) 57 
(n = 1806) 




(~6%); cKIT (1%); 
EGFR (less 
than1%) 
EGFR (17%); PIK3CA 
(14%); ERBB2 (5%); 
cMET (1%)  
ND 
Tothill et al. 
(2013) 64 
(n = 16) 






JAK2 (6%); CCDN1 





ND, not documented, *CTNNB1, MET, PIK3CA; KRAS, BRAF targeted 
sequencing 
Table 3 
Investigational predictive biomarkers of response to immune checkpoint in-
hibitors in CUP.  
Ross et al. (2021) 58 
(n = 303) 
PD-L1 expression ≥ 50%: 14% 
TMB high: 11.6% 
MSI-high: 1% 
Galatica et al. (2018) 66 
(n = 389) 
TMB High : 11.8% 
MSI-H : 1.8% 
PD-L1 expression ≥ 5%: 22.5% 
TMB high: Tumor mutational burden ≥ 16 mutations/megabase. 
MSI-H : microsatellite instability high 
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treatment, showing a median overall survival of 12.5 months, which 
compares favourably with a historical control of 396 patients of CUPs 
patients treated with empiric regimens in four other trials (9.1 months). 
Methodological bias does not allow for highly reliable conclusions on 
the basis of such an indirect comparison. Another non-randomised trial 
assessing the combination of a platinum/taxane regimen with ever-
olimus described a higher ORR (53% versus 26%, P = 0.0097) and a 
better median overall survival (17.8 versus 8.3 months, P = 0.0052) in 
the group of patients with a platinum/taxane-sensitive tissue of origin- 
predicted tumours [93]. 
A randomised phase II trial, conducted by Hayashi and colleagues, 
compared carboplatin/paclitaxel with site-specific treatment, resulting 
in no benefit in the “empirical” arm [88], with definitive conclusions 
difficult to draw because of limitations already described (out-of-date 
standard arm for some primaries, low proportion of lung and breast 
tissue of origin cancers due to environmental and ethnic differences). 
The results of the prospective randomised phase III GEFCAPI 04 trial, 
precisely addressing this question, were presented at the 2019 ESMO 
Congress. The trial used a 92-gene real-time RT-PCR mRNA profiling 
assay essentially providing a more sophisticated phenotype of the un-
known primary tissue of origin based on a gene expression profile al-
gorithm. Based on this profiling, annotated against a large reference 
database, the study randomised between a control arm of empiric 
chemotherapy (gemcitabine/cisplatin doublet) and a personalised 
treatment arm (standard treatment of the suspected primary). The study 
excluded specific subsets with favourable prognosis. It aimed to improve 
median PFS by 3 months (from 5 to 8 months), and stratified for 
geographic site, PS and LDH. With an accrual of 243 patients, this is the 
largest CUP trial so far. GEFCAPI 04 failed to demonstrate an 
improvement in either PFS (HR: 0.95 by central review) or OS (HR: 
0.92). There was a trend for improved OS in patients with cancers whose 
tissue of origin was unlikely to respond to gemcitabine/cisplatin (such as 
melanoma, colorectal and kidney cancer), nevertheless non-significant 
(HR: 0.74, p = 0.3347), owing to the small sub-cohort sizes. Overall, 
outcomes of GEFCAPI 04 confirmed that the prognosis of CUPs 
(excluding specific subsets) remains poor (median PFS of 5 months, 
median OS of 10 months). A plausible explanation of this negative result 
could be that a significant percentage of identified tissue of origin were 
tumours for which a platinum-based regimen is standard-of-care treat-
ment, such as pancreatico-biliary cancer and squamous cell carcinoma. 
This could “annul” the effect of randomisation, as those patients 
received a platinum-based doublet independently of the randomisation 
arm. Moreover, a quarter of patients did not receive tailored treatment 
for multiple reasons (urgent initiation of treatment, dramatic clinical 
deterioration). 
Can Precision Medicine Change The Paradigm? 
Despite celebrated examples of targeted therapy, the initial promise 
of a complete transformation of oncology based on genomics has not 
materialised [94]. Trials exploring the benefit of implementing molec-
ular profiling in advanced cancers showed rather disappointing results, 
leading authors to advocate for innovative approaches in precision 
oncology [95,96]. In the ProfiLER trial, which included 2,579 adult and 
paediatric patients with previously treated metastatic cancer, 
molecular-based treatment has been recommended in 27% of patients, 
with only 6% receiving it, leading to a response in 0.9% of the whole- 
population [97]. The deceiving results of molecular-based recom-
mended therapy trials [96] are not weakening the principles of precision 
oncology per se; they do, nevertheless, bring to light that beyond the thus 
far approved targeted therapies, the magnitude of benefit stemming 
from detailed molecular profiling remains, for now, small. 
Targeted therapy based on molecular analysis 
Targeting specific alteration 
Case-reports describe successful treatment with targeted therapy in 
CUP patients [98–106], yet the reporting bias does not allow for eval-
uation of their real impact. 
Targeted treatment used in an unselected fashion 
The phase II single arm trial that assessed the triple combination of 
everolimus and carboplatin/paclitaxel in untreated CUP patients 
showed promising anti-tumoral activity (ORR: 36% in 45 assessable 
patients); however, without a control arm, the benefit of the addition of 
everolimus is unknown [93]. Furthermore, although the influence of 
tissue of origin identification on outcome was assessed in this study, the 
choice of everolimus was not based on molecular analysis. 
A bevacizumab/erlotinib combination was tested in 51 poor prog-
nosis patients, as first or second line, with only 10% of partial response 
but an overall 71% disease control rate [107]. This led to test the 
addition of bevacizumab/erlotinib to a carboplatin/paclitaxel regimen, 
yielding interesting outcomes with a median overall survival of 12.6 
months and an ORR of 53%, although a non-controlled study [108]. 
Another phase II randomised trial showed that the addition of belinostat 
(a histone deacetylase inhibitor) to a carboplatin/paclitaxel combina-
tion did not led to improved PFS as first line treatment [74]. Table 4 is 
detailing data from phase II trials investigating targeted therapies in 
CUP. 
A paradigm shift recently occurred in oncology with the agnostic- 
histology approval of biomarker-based tissue-agnostic treatments, such 
as NTRK and RET inhibitors targeting the respective fusion-positive 
cancers [109,110]. This could open a possible successful treatment op-
tion for the subset of CUPs that features the above characteristics, 
Table 4 








Ross et al. 
(2021) 58 









AUC 6 and 
paclitaxel 200 
mg/m2   
Response 
rate: 36% 
Median PFS: 4.1 
monthsMedian 
OS: 10.1 months 
Ross et al. 
(2021) 58 


















Median PFS: 3.9 
monthsMedian 
OS: 7.4 months 
Hainsworth 
et al. 108 











15 mg/kg on 
day 1 every 





Median PFS: 8 
monthsMedian 
OS: 12.6 months 
Hainsworth 
et al. 74 
















Median OS: 12.4 




rate: 45% vs 21%; 
p = 0.02 
PFS = progression free survival, OS = overall survival 
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effectively bypassing tissue of origin. Nevertheless, these tumour- 
agnostic biomarkers currently remain exceptions, and their real-life 
impact is not yet clear [111,112]. The tissue of origin, even in the 
emerging era of new tumour-agnostic biomarkers, remains of pivotal 
importance in tumour response. The efficacy of biomarker-driven ther-
apy varies greatly amongst tumour types. For instance, ORR to anti-PD1 
pembrolizumab in MSI-H tumours varied from 57% in endometrial 
cancers to 18% in pancreatic cancers and 0% in brain tumours [113]. 
BRAF inhibition is a striking illustration among others: the efficacy of 
vemurafenib in targeting the BRAF V600E mutation observed in mela-
noma patients [114] is not reproducible in colon cancers [115,116]. The 
Cancer Genome Atlas analysis of 11,286 specimens confirmed that cell- 
of-origin pattern is the dominating classification of cancers [117]. 
In known primary tumours, mechanisms for primary failure to tar-
geted approaches, or secondary resistance, has been described: high 
clonal variability and heterogeneity with clonal selection of resistant 
clones [118], concomitant resistance mutations, redundancy of onco-
genic pathways [119]. CIN is known to confer multidrug resistance 
[120]. In which manner these known resistance mechanisms are 
important specifically in CUPs is not perfectly understood. 
Role of immune checkpoint inhibitors (CPI) 
A greater number of patients presenting with CUPs are treated with 
immune checkpoint inhibitors (CPI): either inside clinical trials, through 
the FDA approval in case of for microsatellite instability-high (MSI-H) or 
mismatch repair deficient tumours (MMRd)[121], or off-label. Efficacy 
biomarkers are needed across cancer types for CPI, and the same applies 
for CUP. Overall, PD-L1 expression alone is not a sufficient biomarker to 
predict response to CPI across cancer types [122–124]. Tumour muta-
tional burden (TMB) as a predictive biomarker to CPI treatment has 
shown clinical impact in some studies [125–128]. However, the real 
predictive value of TMB remains unclear and needs further investigation 
[129]. 
Anecdotal cases showed clinical activity of CPI in CUPs irrespective 
of the presumed tissue of origin [130,131]. NivoCUP, an open-label 
phase II trial, is the first trial in this setting to be reported. The effi-
cacy of nivolumab in the unfavourable subset of CUP patients was 
assessed, with ORR as the primary endpoint [132]. Most of patients 
(80.3%) were previously treated. In this population (n = 45), the ORR 
was 22%, with two complete response (4.4%), a disease-control rate of 
53.3% and a median duration of response of 12.4 months. Median PFS 
and OS in this group were 4.0 months and 15.9 months respectively. The 
reported median PFS was rather short without a plateau that would 
indicate long term responders. Of note, among the 45 patients previ-
ously treated, 20% had 2 prior lines of therapy and 22% has 3 prior lines, 
which obviously represents a very highly selected population, thus 
making cross-trial comparison meaningless. In the same work, a very 
low number of patients were treated upfront with nivolumab with 
18.2% ORR. There is indeed signal of efficacy, with the caveat of highly 
selected patients. The need for predictive biomarkers in order to identify 
the 20% of CUP patients that will indeed respond to CPI treatment is 
crucial. 
Other trials addressing the role of CPI in CUPs are ongoing. Selection 
of patients for treatment, based on clinical features and biomarkers, are 
critical. The ongoing CUPISCO trial includes an atezolizumab mono-
therapy arm for the TMB-high patients, and a combination chemo-
therapy/atezolizumab arm for patients with TMB-low or unknown 
tumours. 
While awaiting these results, we must be aware of the specific 
phenotypic and biologic pattern of the unfavourable prognostic CUPs 
tumour: how chromosomal instability, a hallmark of unfavourable 
CUPs, could impact response to CPI remains an open question [43,44]. 
What if we use precision medicine as a means to an end? 
It is very likely that a subset of CUP patients in the unfavourable 
subgroup would derive more benefit from molecular-driven treatment 
than classical chemotherapy. Only a prospective study could identify the 
real proportion of these patients. When such data are available, they 
could bring an argument for incorporating molecular analyses, such as 
NGS, into the initial diagnostic work-up of CUP; this was recently 
advocated for patients for whom a dominant tissue of origin has not been 
identified [133]. 
The reality is that guiding treatment based on optimisation of tissue 
of origin identification has thus far failed to improve outcomes. As an 
alternative approach, instead of aiming to identify tissue of origin 
(phenotypic similarities), we could aim to identify the driver changes 
behind these aggressive CUP lesions (genotypic driver changes) that can 
be therapeutically targeted, eventually ignoring the tissue of origin. A 
integrated approach could combine the two, generating both a detailed 
tissue of origin -phenotypical analysis and a comprehensive genomic 
profiling in the aim of identifying targetable alterations, which 
approximately one-third of CUPs seem to harbour [58]. CUPISCO is an 
ongoing phase II randomised trial that aims to explore molecularly- 
guided therapy for CUPs, using a platinum-based chemotherapy 
comparator arm and a number of targeted therapies globally covering 
for all targetable alterations with a proven benefit in oncology 
(NCT03498521). CUPISCO is designed to show whether this approach 
can improve outcomes. After 3 cycles of platinum-based chemotherapy, 
non-progressing patients are randomised between the investigational 
arm of maintenance therapy based on NGS analysis and a control arm 
(further chemotherapy). This “switch maintenance” design selects for 
patients responding to standard chemotherapy and positively primes the 
study for better results, effectively excluding the poor responder patients 
with very poor prognosis; per CUPISCO protocol, the latter patients will 
receive second line molecularly guided therapy, and results will be 
analysed on an exploratory basis. Results are highly anticipated. Should 
CUPISCO attain its objective, coupled with the continuously enlarging 
range of targeted therapies, it could bring about a meaningful change in 
the outcomes of the disease, for which there has been little success so far. 
Nonetheless, whether an achieved PFS benefit -the study primary 
endpoint- would translate in either overall survival benefit or better 
quality of life in this lethal disease remains the main clinically mean-
ingful questions. 
However, the CUPISCO investigators have already reported on bar-
riers in enrolling patients. Reporting on the first 157 patients, 58% failed 
the screening process for several reasons such as issues in identifying this 
subset of CUP patients, insufficient quality or quantity of tissue available 
for screening molecular analysis and the declining performance status of 
prospective candidates [134]. 
There is a clear need to identify driver genomic abnormalities out of 
the potential list of pathogenic aberrations identified through molecular 
profiling. It might actually be more pertinent to spot the differences 
instead of the similarities with the presumed tissue of origin. In this 
process, the critical assessment of profiling-identified changes, the 
interpretation of variants of uncertain significance and the identification 
of potential germline variants are challenges that require multidisci-
plinary review and the linking to clinical trials networks [135]. This 
should be made within molecular tumour boards. 
Accrual is a major issue in running specific CUPs trials, explaining 
why only four of them are actually recruiting (Table 5). 
Conclusion 
CUPs could be viewed as the quintessence of oncology, with many 
transversal biological issues, challenges that are found across oncology 
in general, but crucially with urgently needed answers to improve pa-
tient’s clinical outcomes. Although a highly heterogeneous group of 
cancers, CUPs can be categorised in two very distinct groups, at levels of 
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biology, clinical presentation, treatment strategies and prognosis. The 
first group of specific subset CUPs behave closely like their counterpart 
known primaries, and benefit from same treatment strategies leading to 
same outcomes. Whether molecular profiling can enlarge this group of 
good-prognosis, specific-subset CUPs is an interesting point that remains 
to be seen. 
The vast majority of CUP patients belongs to the unfavourable, non- 
specific subset CUP group. They present with very poorly differentiated 
tumours, high chromosomal instability, aggressive and unpredictable 
metastatic pattern, and poor prognosis. A true “molecular signature” has 
not yet been identified, yet chromosomal instability seems to be a 
hallmark of unfavourable CUPs. The main issue pertains to this unfav-
ourable subgroup of CUP patients, where almost no improvement has 
been achieved for decades. Recent randomised trials have shown that 
tissue of origin classifiers used to guide treatment do not modify out-
comes. Molecular analysis in order to find matched targeted therapies 
could probably select a proportion of patients that could benefit from 
these treatments, but prospective evidence is awaited. Within this 
context, whether immune checkpoint inhibitors could be beneficial re-
mains an ongoing question. 
A promising area of research focus could be the possibility of iden-
tifying a “feature signature” within the unfavourable group of CUPs that 
could be found in an “-omics” levels and could transcend the tissue of 
origin pattern (metabolism, microenvironment, non-coding DNA region, 
epigenetics). How to target chromosomal instability is also of major 
interest, as well as how to combine treatment to prevent acquired 
resistance. 
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